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 Abstract 
Context: Current evidence-based management for clinically localised prostate cancer 
includes active surveillance, surgery, external beam radiotherapy (EBRT) and brachytherapy. 
The impact of these treatment modalities on quality of life (QoL) is uncertain. 
Objective: To systematically review comparative studies investigating disease-specific QoL 
outcomes as assessed by validated cancer-specific Patient Reported Outcome Measures with 
at least 1 year of follow-up after primary treatment for clinically localised prostate cancer. 
Evidence acquisition: Medline, Embase, AMED, PsycINFO and the Cochrane Library were 
searched to identify relevant studies. Studies were critically appraised for risk of bias. A 
narrative synthesis was undertaken. 
Evidence synthesis: Of 11,486 articles identified, 18 studies were eligible for inclusion 
including 3 RCTs (follow-up range: 60-72 months) and 15 non-randomised comparative 
studies (follow-up range: 12-180 months) recruiting a total of 13,604 patients. Two RCTs 
recruited small cohorts and only one was judged as low risk of bias. The quality of evidence 
from observational studies was low to moderate. For a follow-up of up to six years, active 
surveillance was found to have the lowest impact on cancer-specific QoL, surgery had a 
negative impact on urinary and sexual function when compared to active surveillance and 
EBRT, while EBRT had a negative impact on bowel function when compared to active 
surveillance and surgery. Data from one small RCT reported that brachytherapy has a 
negative impact on urinary function 1 year post treatment, but no significant urinary toxicity 
was reported at 5 years. 
Conclusions: This is the first systematic review comparing the impact on cancer- specific 
QoL of different primary treatments for men with clinically localised PCa, using validated 
cancer-specific PROMs only. There is robust evidence that choice of primary treatment for 
localised prostate cancer has distinct impacts on patients’ QoL. This should be discussed in 
detail with patients during pre-treatment counselling. 
Patient Summary: Our review of the current evidence suggests that for a period of up to six 
years after treatment, men with localised prostate cancer who were managed with active 
surveillance reported high levels of QoL. Men treated with surgery reported mainly urinary 
and sexual problems, while men treated with external beam radiotherapy reported mainly 
bowel problems. Men eligible for brachytherapy reported urinary problems up to a year after 
therapy, but then their QoL returned gradually to as it was before treatment.  
 
 
 
 
 
 
 1. Introduction 
Since the introduction of PSA testing, there has been a substantial shift to a more favourable 
stage in newly-diagnosed prostate cancer (PCa), with approximately 81% of cases being 
diagnosed as clinically localised [1]. Currently, evidence-based management for clinically 
localised PCa includes active surveillance (AS), surgery, external beam radiotherapy (EBRT) 
and brachytherapy (BT) [2]. Knowledge of the adverse events of different management 
options is critical for making informed treatment decisions, considering that the survival 
benefit is uncertain, especially in men with favourable-risk PCa [3].  
The adverse effects of primary treatments for localised disease can negatively impact on 
disease-specific quality of life (QoL) [4]. The concept of 'quality of life' is subjective, 
however, in cancer cohorts, specific tools or Patient Reported Outcome Measures (PROMs) 
have been developed and validated. These questionnaires assess common issues that affect 
men after PCa diagnosis and treatment and generate scores, which reflect the impact on 
perceptions of health-related quality of life (HRQoL). It is currently unclear which primary 
treatment for localised disease offers superior disease-specific QoL outcomes. The primary 
objective of this systematic review was to compare cancer-specific QoL data as measured by 
PROMs for intermediate (1-10 years) to long-term (>10 years) follow-up, among competing 
treatments. 
 
2. Evidence acquisition 
2.1 Search strategy 
The review was performed according to Preferred Reporting Items for Systematic Reviews 
and Meta-analyses guidelines [5] and Cochrane review principles [6]. An experienced 
research librarian performed the search strategy in consultation with a multi-disciplinary 
panel of expert clinicians and patient representative (EAU Prostate Cancer Guideline panel). 
The database searched were EMBASE, MEDLINE, AMED, PsycINFO, Cochrane Database 
of Systematic Reviews, and Cochrane Central Register of Controlled Trials. Searches were 
limited to studies published from the year 2000 onwards. No language restrictions were 
imposed. Full details of the search strategies used are described in Appendix 1. 
All abstracts and full text articles were screened by two independent reviewers (MIL, MAL). 
Disagreement was resolved by discussion; if no agreement was reached, a third independent 
party acted as an arbiter (LB). 
2.2 Types of study design included 
Randomised and non-randomised comparative studies where outcome data was collected 
prospectively after primary intervention for prostate cancer was initiated (see section 2.4 for 
included interventions) with a sample size of at least 10 patients per arm, reporting cancer-
specific QoL outcomes measured by validated PROMs [7] with at least 12 months of follow-
up, were eligible for inclusion. 
2.3 Types of participants included 
The study population was adult men (≥18 years of age) diagnosed with clinically localised 
PCa (T1-T2c) that had not undergone any previous treatment prior to their primary treatment 
for PCa (with the exception of neoadjuvant Androgen Deprivation Therapy [ADT] preceding 
radiotherapy). 
2.4 Types of interventions included 
The following interventions were eligible for inclusion: 
(1) Active surveillance/monitoring (as defined by primary authors) 
(2) Radical prostatectomy (Open or Laparoscopic or Robot-Assisted) 
(3) Radiotherapy (3D conformal or Intensity Modulated [IMRT] or Stereotactic 
radiotherapy [SBRT]) +/- brachytherapy boost (Low Dose Rate [LDR] or High 
Dose Rate [HDR]); or Radiotherapy delivered with or without 
neoadjuvant/concurrent/adjuvant ADT for the treatment of localised PCa 
(4) Brachytherapy alone (LDR or HDR) 
 
Studies reporting comparisons between any of the above treatments were included. Studies 
reporting within treatment comparisons only (e.g. radiotherapy vs radiotherapy in 
combination with ADT) were excluded, as the aim of this review was to compare QoL 
outcomes between different management options. 
2.5 Types of outcome measures included 
The primary outcome of this review was specified a priori and included cancer-specific QoL 
after primary cancer treatment, assessed by a validated PROM as defined by authors. In 
addition, a list of validated PROMs was used to identify potentially relevant studies and 
incorporated into the search strategy [7]. Studies using non-cancer specific PROMs or studies 
reporting cancer specific QoL using a non-validated tool were excluded, as were those studies 
reporting incomplete data from sub-domains of QoL PROMs. Secondary outcomes were sub-
domains of QoL PROMs related to PCa QoL e.g. sexual function, urinary function and bowel 
function. 
2.6 Assessment of risk of bias and confounding 
Randomised controlled trials (RCTs) risk of bias (RoB) assessment was undertaken using the 
recommended tool in the Cochrane Handbook for Systematic Reviews of Interventions [6].  
In non-randomised comparative studies (NRCSs), RoB was assessed using additional 
domains to assess the risk of confounders, which were developed a priori with clinical 
content experts (EAU Prostate Cancer Guideline Panel). This is a pragmatic approach 
informed by methodological literature pertaining to assessing RoB in NRCSs [8, 9]. The 
main confounding factors identified included baseline QoL score, age, co-morbidities (any 
classification) and baseline Gleason score.  
2.7 Data analysis 
A data extraction form was developed a priori to collect information on study design, 
participant demographics, characteristics of interventions, and outcome measures. Two 
reviewers independently extracted data relating to the pre-specified outcomes. Descriptive 
statistics were used to summarise baseline characteristic data. For studies with more than two 
intervention groups, only the intervention groups relevant to the review were selected. If 
relevant data could be extracted and it was appropriate to do so, a meta-analysis of RCT data 
was planned. For studies with multiple publications, only the most up-to-date or complete 
data for each outcome was utilized. If meta-analyses of RCTs were inappropriate, a narrative 
synthesis of the evidence was performed. A narrative synthesis was undertaken for NRCSs 
[10]. 
 
3. Evidence synthesis 
3.1 Quantity of evidence identified 
The study selection process is outlined in Figure 1. A total of 18 studies were eligible for 
inclusion: 3 RCTs [11-13] and 15 NRCSs [14-30] of which one NRCS [23, 24, 26] had 
multiple publications. Ultimately, a total of 13,604 patients were recruited (2,011 from RCTs 
and 11,593 from NRCSs). 
 
3.2 Characteristics of the included studies 
Tables 1 and 2 present the baseline study characteristics for the 3 RCTs and 15 NRCSs, 
respectively. Due to heterogeneity of study PROMs data, a meta-analysis was not performed 
and consequently, data were summarised narratively instead. 
 
3.3 Risk of bias and quality assessment of the included studies 
Figures 2a and 2b present the RoB summary and confounder assessment for the three RCTs 
[11-13] and fifteen NRCSs [14-30]. As it was not possible to blind the participant to their 
intervention, all RCTs [11-13] had a high risk of bias for blinding of participants but we did 
not judge that this necessarily compromised study quality. One RCT [11] was also judged to 
have high selection bias (as only 19% of patients were randomly assigned to treatment arms), 
high bias due to closing prematurely and unclear detection bias, while another [13] was 
judged to have unclear selection and funding bias. 
The NRCSs had a high risk of selection, performance, and detection biases. The risks of 
reporting bias were low, while risks of attrition bias were moderate. All confounders were 
measured and corrected for, in five studies [17, 21, 26, 28, 30]. 
 
3.4 Comparisons of interventions results 
3.4.1. Data from RCTs 
Statistically significant differences, for QoL outcomes between or within treatment groups at 
the latest follow-up of each RCT [11-13] are shown in Table 3. The complete summary of the 
outcome results can be found in Supplementary Table 1.  
 
3.4.1.1 RP vs EBRT vs Active monitoring 
Data were obtained from the recently published study ProtecT trial [12], where 1643 men 
randomised to active monitoring, RP or EBRT. The trial predominantly enrolled men with 
low and intermediate risk PCa. Trial retention and completion of follow-up assessments were 
higher than 85% for most outcome measures. Analyses were performed according to an 
intent-to-treat basis. Approximately 50% (291) of men who initially underwent active 
monitoring had either surgery or radiotherapy by the end of November 2015. 
Importantly, the study reported no difference in EORTC QLQ-C30 assessed global quality of 
life, up to 5 years of follow-up. However, Expanded Prostate Cancer Index Composite 
(EPIC) urinary summary scores were worse in men treated with RP compared to active 
monitoring or EBRT (88.7 vs 89.0 vs 91.4, respectively) as were urinary incontinence (80.9 
vs 85.8 vs 89.4, respectively) and sexual summary, function and bother scores (32.3 vs 40.6 
vs 41.3 for sexual summary, 23.7 vs 32.5 vs 32.7 for sexual function and 51.4 vs 57.9 vs 60.1 
for sexual bother, respectively) at 6 years of follow-up. For men receiving EBRT, EPIC 
bowel scores deteriorated initially and although they improved after the first year, they were 
still poorer compared to active monitoring and RP at 6 years post-treatment in all domains: 
summary (91.2 vs 93.2 vs 93.0, respectively), function (90.8 vs 92.3 vs 92.3, respectively) 
and bother (91.7 vs 94.2 vs 93.7, respectively). 
 
3.4.1.2 RP vs BT 
For the comparison of RP vs BT, data were obtained from two RCTs. The SPIRIT trial [11] 
enrolled 168 men with low-risk PCa who received either RP or LDR BT. The investigators 
using the EPIC tool, found a statistically significant difference in the urinary and sexual 
domain, favouring men treated with LDR BT at a mean follow up of 5.2 years. These results 
should be interpreted with caution since only a minority of patients were randomly assigned 
to treatment arms (19%) and the trial was closed prematurely due to poor accrual. 
Another RCT [13] that recruited 200 patients with low-risk PCa, reported that urinary 
irritation was statistically significantly worse in the LDR BT arm when compared with pre-
treatment values, while urinary incontinence was more common - although not statistically 
significantly different - in the nerve-sparing RP (NSRP) arm, at 1 year of follow up. 
However, there were no significant differences in EORTC-QLQ-C30/PR25 scores at 5 years 
of follow up. It is notable that only within group tests were reported in this trial.  
 
3.4.2. Data from NRCSs 
Statistically significant differences, for QoL outcomes between or within treatment groups at 
the latest follow-up of each NRCS [14-30] are shown in Table 4. The complete summary of 
the outcome results can be found in Supplementary Table 2. 
 
3.4.2.1 RP vs EBRT vs BT 
An observational study [25] compared men undergoing NSRP vs non-NSRP vs EBRT vs BT 
using the University of California, Los Angeles (UCLA) Prostate Cancer Index (PCI) tool. 
The study was characterised by poor participant retention at 5 and 10 years. However, at 2 
years of follow-up (81% cohort retention), authors using NSRP as a reference value, reported 
that men treated EBRT were more likely to have a clinically significant decline [(CSD) at 
least half standard deviation from baseline] in bowel function and bother score, while men 
treated with BT were more likely to have a CSD in bowel bother score. Conversely, men 
were less likely to have a CSD in urinary and sexual function for BT and EBRT. These 
results are analogous with results from two other studies [14, 21]. The first [14] used the 
UCLA-PCI tool and for a follow up of up to five years reported that patients treated with 
EBRT had better sexual and urinary but worse bowel function than those treated with RP. BT 
patients had better sexual function, sexual bother and urinary function compared with RP 
patients, however, they had worse bowel function, bowel bother and urinary bother. The 
second study [21] assessed QoL scores at 3 years using the EPIC questionnaire. In 
comparison with NSRP, EBRT and BT caused significantly worse urinary 
irritative/obstructive adverse effects but less urinary incontinence and sexual dysfunction. 
EBRT also caused worse bowel and hormonal adverse effects. 
Sanda et al [27] using the EPIC tool, compared CSDs in QoL scores within treatment groups 
only, from baseline to 2 years post treatment. Patients in the RP group reported CSDs in 
urinary continence and sexual function, however urinary irritation/obstruction scores 
significantly improved after surgery. EBRT was also associated with improvement in urinary 
irritation/obstruction scores but with reduced QoL related to bowel function and vitality. 
Patients treated with EBRT plus ADT also reported CSD in sexual function. Surprisingly, 
patients in the BT group reported significant reduction in all QoL subdomain scores except 
vitality. 
 
3.4.2.2 RP vs EBRT or AS 
Four studies [23, 24, 26, 28-30] reported QoL outcomes in men with localised PCa 
undergoing RP or EBRT, however in one [29], authors did not compare differences in QoL 
scores between treatments. In the most recent update of the Prostate Cancer Outcomes Study 
(PCOS) [26], the authors compared QoL scores at 2, 5 and 15 years after primary therapy. 
Although men undergoing RP had significantly higher rates of incontinence and erectile 
dysfunction and lower rates of bowel urgency at 2 and 5 years, these rates were similar to 
those in the EBRT group at 15 years. Barocas et al [30] using the EPIC questionnaire, 
reported that RP was associated with a greater decrease in sexual function and urinary 
incontinence than EBRT at 3 years of follow up. No clinically meaningful differences existed 
in bowel function beyond 12 months. The fourth study [28] had a limited follow up and 
reported that men who underwent RP experienced significant declines in urinary and sexual 
function when compared to EBRT. 
Regarding comparison of QoL outcomes between RP and AS,  Jeldres et al [17] in a cohort of 
patients with low-risk PCa reported similar results to ProtecT trial [12], as at 3 years of 
follow up, patients who underwent surgery had significantly poorer urinary, sexual function 
and sexual bother scores. 
 3.4.2.3 BT vs RP or EBRT 
Four studies assessed QoL outcomes in patients with localised PCa after BT or RP [15, 18-
20]. The investigators in two studies [18, 20] included a small number of patients with a 
limited follow up of 12 months and using the UCLA-PCI questionnaire, reported statistically 
worse sexual function for patients in the RP arm. Namiki et al [20] also reported significantly 
better urinary function scores for patients treated with BT. Another small study [15] reported 
that at 12 months sexual function was impaired significantly in patients after non-NSRP but 
not after NSRP when compared to patients treated with BT. In the largest prospective study 
[19], authors compared patients treated with RP, brachytherapy and cryotherapy. Statistical 
comparison for QoL outcomes between RP and BT cannot be made (as cryotherapy is not 
included in this review), nevertheless at 3 years of follow up BT patients tended to have 
better sexual and urinary scores.  
Only 2 studies [16, 22] compared QoL after BT and EBRT using the EPIC questionnaire. 
Pinkawa et al [22] reported that BT was associated with statistically significantly higher 
urinary toxicity at 16 months. Evans et al [16] reported similar results, however SBRT was 
associated with lower bowel toxicity than BT at 2 years.  
 
3.5 Discussion 
3.5.1 Principal findings 
The current review synthesises the existing evidence regarding cancer-specific QoL 
outcomes, of competitive treatments for clinically localised PCa. QoL is an important 
endpoint in PCa treatment and recently the COMPACTERS Study group, which developed a 
core outcome set for trials of effectiveness, identified QoL as an outcome which should be 
measured in all clinical trials of localised PCa [31]. Outcomes were measured by PROMs and 
the three most mainly used among the included studies were: EPIC, UCLA-PCI and EORTC 
QLQ-C30. 
The ProtecT trial [12] provides level 1 evidence for the different effects of PCa treatments on 
disease-specific QoL. No difference was found among treatment modalities in global quality 
of life at 5 years. However, surgery had a negative effect on urinary continence and sexual 
function, EBRT was associated with a negative effect in bowel function which was more 
intense the first year after treatment, while active monitoring had the lowest impact on 
disease-specific QoL at 6 years. The PCOS 5-year results [26], confirm that men who 
underwent RP had a higher prevalence of urinary incontinence and erectile dysfunction, 
while men treated with EBRT had a higher prevalence of bowel dysfunction. Results from 
ProtecT trial are also comparable with the findings of the PIVOT Trial [32] as authors 
reported that at 2 years, urinary incontinence and erectile dysfunction were significantly more 
common among men who were assigned to RP when compared to men managed with 
observation.  
Most other observational studies provide similar, consistent intermediate-term results for RP 
and EBRT. However, in a recently published study [30], investigators reported that although 
EBRT was associated with a negative effect in bowel function, the difference in bowel 
domain score was below the threshold for clinical significance 12 months after treatment. As 
81% of patients in the EBRT arm of the study received IMRT, these data suggest that the risk 
of side effects in contemporary treatments may be slightly less. Another discrepancy noted, is 
that while some studies report worse declines in urinary function after surgery [14, 25, 28], 
others report that surgery resulted in more incontinence but less irritating/obstructive 
symptoms than EBRT [21, 27, 30]. This variation could be explained by the use of different 
PROMs. Studies reporting urinary function decline after RP use the UCLA-PCI tool which 
focuses primarily on urinary incontinence, while studies reporting less irritative/obstructive 
symptoms use the EPIC tool. EPIC addresses irritative and obstructive voiding symptoms and 
provides a more comprehensive assessment of urinary QoL [33]. Urinary irritation symptoms 
are sometimes said to be worse with EBRT, however, this was not confirmed by ProtecT trial 
[12].  
Regarding the effect of AS on QoL, as recently highlighted [34] there is a lack of data. We 
were able to identify only one NRCS [17] including patients undergoing AS, which similarly 
to ProtecT trial [12] reported no major perturbations to their cancer-specific QoL.  
With respect to BT cancer-specific QoL outcomes, the best available evidence come from 
one small RCT [13]. The authors compared post-treatment QoL scores for patients 
undergoing BT and NSRP with their baseline scores only (there is no comparison between 
groups available), and they reported that at 1 year, BT had a negative impact on urinary 
irritative symptomatology. This result is consistent among all observational studies that use 
the EPIC tool, which addresses irritative-obstructive symptomatology [16, 21, 22, 27]. 
Unexpectedly, authors also reported that both BT and NSRP had no significant impact on 
QoL 5 years after treatment. Conversely, the SPIRIT trial [11], which directly compared QoL 
outcomes for BT and RP found a statistically significant difference in favour of BT in the 
urinary and sexual domains. In that trial though, the small difference in the overall mean 
scores in the urinary domain may have questionable clinical significance.   
As only a small proportion of patients with early stage PCa progress to metastatic disease and 
die from cancer within 10–15 years [35], understanding the long term impact of treatment on 
disease-specific QoL is critical. This systematic review revealed an important knowledge gap 
in the evidence base, as we were able to identify only one NRCS [26] that reported QoL 
outcomes at a follow up of more than 10 years. Interestingly, data from the PCOS [26], 
showed that there were no significant differences in the adjusted odds of urinary 
incontinence, bowel dysfunction or erectile dysfunction between RP and EBRT at 15 years. 
PCOS provided two further important observations; firstly, at the end of follow up, the 
prevalence of erectile dysfunction was very high (≥80%) in both treatment arms and secondly 
patients had significant declines in sexual and urinary function over the duration of follow up. 
These observations have also been reported for patients undergoing RP and watchful waiting 
(WW), in the most recent publication of the SPCG-4 trial, regarding HRQoL outcomes [36], 
for a median follow up of 12.2 years. While it would be difficult to determine whether these 
declines are the consequence of treatment, advancing age or both, data from PLCO Trial 
comparing a sample of screened PCa survivors to a sample of screened noncancer controls, 
suggested that these persistent symptoms were due to treatment [37].   
 
3.5.2 Strength and limitations of the review 
The strengths of this review are the systematic, transparent, and robust approach taken to 
examine the evidence base, including the use of Cochrane review methodology, RoB and 
confounding assessment and adherence to PRISMA guidelines. The clinical question was 
prioritised by a multidisciplinary panel of clinical experts, methodologists, and patient 
representatives (EAU Prostate Cancer Guideline panel), and the work was undertaken as part 
of the panel’s clinical practice guideline update for 2017. The inclusion criteria restricted the 
review to studies reporting data on cancer-specific QoL outcomes, measured by validated 
PROMs only. This approach ensured a comprehensive review of the literature, while 
maintaining methodological rigour. 
It is important for the authors of this review to acknowledge several limitations. The number 
of RCTs providing level 1 evidence is limited (i.e. three) two of which recruited small 
cohorts. The quality of the evidence obtained from observational studies is problematic in 
relation to high risk of selection, performance, and detection biases and the minority of the 
studies accounting for our a priori identified confounders. There is large methodological 
heterogeneity among studies (as different PROMS being used to measure the same outcome, 
along with outcomes being measured at different time points), as well as heterogeneity 
regarding outcome reporting. An additional limitation is the fact that treatment arms in many 
included studies differ from contemporary care (i.e IMRT), as newer interventional 
techniques, especially newer EBRT techniques, may result in a lower risk and severity of side 
effects.  
 
3.5.3 How does this systematic review compare with other systematic reviews? 
To our knowledge, this is the first systematic review comparing the impact on cancer- 
specific QoL of different primary treatments for men with clinically localised PCa, using 
outcomes measured by validated cancer-specific PROMs only. The most recent systematic 
review [38] including mostly single treatment cohorts, is over four years out of date (searches 
up to January 2013) and highlighted the lack of sufficient quality data to make 
recommendations to patients about QoL outcomes. Similar were the results of two previous 
reviews, which concluded that there was a paucity of clinically important information from 
high-quality RCTs on this topic [39, 40]. In another review by Chou et al [41], that included 
not only HRQoL outcomes, the authors reported that RP was associated with increased risk 
for urinary incontinence and erectile dysfunction, while EBRT was associated with increased 
risk for erectile and bowel dysfunction when compared with WW. Our systematic review 
differs from others with regards to the methodology, the strict inclusion and exclusion criteria 
and the robust methods used to synthesise the evidence and analyse the data. These are the 
principal strengths of our study. 
 
4. Conclusion 
Based on currently available evidence, choice of primary treatments for clinically localised 
PCa have a distinct impact on cancer-specific QoL, for a period of up to 6 years following 
treatment. Men managed with AS have good overall QoL scores, which are comparable or 
better than those of patients undergoing radical treatments. Surgery has a more pronounced 
negative impact on urinary and sexual function when compared to AS and EBRT, while 
EBRT has a more pronounced negative impact on bowel function when compared to AS and 
RP. Data from one small RCT including patients with low-risk disease reported that 
brachytherapy has a negative impact on urinary function at 1 year, but there are no significant 
differences in cancer-specific QoL 5 years after treatment. The review findings support the 
assertion that AS provides a good alternative to radical treatments in patients in whom it is 
desirable to prioritise QoL outcomes. The findings provide a basis for informing patients and 
clinicians regarding the impact of radical treatments on QoL. 
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